BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Lu S, Wang J, Liu S, Hung C, Chen C, Tung H, Chen T, Huang W, Lee C, Chen C, Changchien C. Thrombocytopenia as a surrogate for cirrhosis and a marker for the identification of patients at high-risk for hepatocellular carcinoma. Cancer 2006;107:2212-22. [DOI: 10.1002/cncr.22242] [Cited by in Crossref: 103] [Cited by in F6Publishing: 102] [Article Influence: 6.9] [Reference Citation Analysis]
Number Citing Articles
1 Kumada T, Toyoda H, Kiriyama S, Tanikawa M, Hisanaga Y, Kanamori A, Tada T, Tanaka J. Characteristics of elderly hepatitis C virus-associated hepatocellular carcinoma patients: Elderly HCV-associated HCC patients. J Gastroenterol Hepatol 2013;28:357-64. [DOI: 10.1111/jgh.12057] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
2 Akkiz H, Carr BI, Yalçın K K, Guerra V, Kuran S, Altıntaş E, Üsküdar O, Karaoğullarından Ü, Özakyol A, Tokmak S, Yücesoy M, Bahçeci Hİ, Ülkü A, Akçam T, Yalçın Polat K, Ekinci N, Şimşek H, Örmeci N, Sonsuz A, Demir M, Kılıç M, Uygun A, Ballı T, Demir A, Arslan B, Doran F. Characteristics of Hepatocellular Carcinoma Aggressiveness Factors in Turkish Patients. Oncology 2018;94:116-24. [PMID: 29207378 DOI: 10.1159/000484564] [Cited by in Crossref: 6] [Cited by in F6Publishing: 9] [Article Influence: 1.5] [Reference Citation Analysis]
3 Maan R, de Knegt RJ, Veldt BJ. Management of Thrombocytopenia in Chronic Liver Disease: Focus on Pharmacotherapeutic Strategies. Drugs 2015;75:1981-92. [PMID: 26501978 DOI: 10.1007/s40265-015-0480-0] [Cited by in Crossref: 26] [Cited by in F6Publishing: 23] [Article Influence: 5.2] [Reference Citation Analysis]
4 Lok AS, Seeff LB, Morgan TR, di Bisceglie AM, Sterling RK, Curto TM, Everson GT, Lindsay KL, Lee WM, Bonkovsky HL. Incidence of hepatocellular carcinoma and associated risk factors in hepatitis C-related advanced liver disease. Gastroenterology. 2009;136:138-148. [PMID: 18848939 DOI: 10.1053/j.gastro.2008.09.014.] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
5 Casadei Gardini A, Foschi FG, Conti F, Petracci E, Vukotic R, Marisi G, Buonfiglioli F, Vitale G, Ravaioli F, Gitto S, Verucchi G, Lenzi M, Bolondi L, Mazzella G, Brillanti S, Andreone P. Immune inflammation indicators and ALBI score to predict liver cancer in HCV-patients treated with direct-acting antivirals. Digestive and Liver Disease 2019;51:681-8. [DOI: 10.1016/j.dld.2018.09.016] [Cited by in Crossref: 26] [Cited by in F6Publishing: 24] [Article Influence: 13.0] [Reference Citation Analysis]
6 Carr BI, Guerra V, Giannini EG, Farinati F, Ciccarese F, Rapaccini GL, Di Marco M, Benvegnù L, Zoli M, Borzio F, Caturelli E, Chiaramonte M, Trevisani F. Low alpha-fetoprotein HCC and the role of GGTP. Int J Biol Markers. 2014;29:e395-e402. [PMID: 24832180 DOI: 10.5301/jbm.5000092] [Cited by in Crossref: 8] [Cited by in F6Publishing: 12] [Article Influence: 1.1] [Reference Citation Analysis]
7 Lee HJ, Eun R, Jang BI, Kim TN. Prevention by Lamivudine of hepatocellular carcinoma in patients infected with hepatitis B virus. Gut Liver. 2007;1:151-158. [PMID: 20485632 DOI: 10.5009/gnl.2007.1.2.151] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 0.4] [Reference Citation Analysis]
8 Shehta A, Han HS, Ahn S, Yoon YS, Cho JY, Choi YR. Post-resection recurrence of hepatocellular carcinoma in cirrhotic patients: Is thrombocytopenia a risk factor for recurrence? Surg Oncol 2016;25:364-9. [PMID: 27916167 DOI: 10.1016/j.suronc.2016.08.002] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.6] [Reference Citation Analysis]
9 Orzechowska D, Klimowicz K, Stępień A, Mikuła T, Sapuła M, Wiercińska-Drapało A. Change in γ-glutamyl transpeptidase activity as a useful tool in identifying a group of patients with elevated risk of hepatocellular carcinoma development after DAA treatment of chronic hepatitis C. Clin Exp Hepatol 2021;7:93-100. [PMID: 34027121 DOI: 10.5114/ceh.2021.104466] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
10 Sherman M. Hepatocellular carcinoma: New and emerging risks. Dig Liver Dis. 2010;42 Suppl 3:S215-S222. [PMID: 20547306 DOI: 10.1016/s1590-8658(10)60508-7] [Cited by in Crossref: 20] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
11 Wu CK, Chang KC, Hung CH, Tseng PL, Lu SN, Chen CH, Wang JH, Lee CM, Tsai MC, Lin MT, Yen YH, Hu TH. Dynamic α-fetoprotein, platelets and AST-to-platelet ratio index predict hepatocellular carcinoma in chronic hepatitis C patients with sustained virological response after antiviral therapy. J Antimicrob Chemother 2016;71:1943-7. [PMID: 27073265 DOI: 10.1093/jac/dkw097] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 3.2] [Reference Citation Analysis]
12 Ryu T, Takami Y, Wada Y, Hara T, Sasaki S, Saitsu H. Actual 10-Year Survival After Surgical Microwave Ablation for Hepatocellular Carcinoma: A Single-Center Experience in Japan. Ann Surg Oncol. 2019;26:4126-4133. [PMID: 31359277 DOI: 10.1245/s10434-019-07646-8] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 4.5] [Reference Citation Analysis]
13 Chang KC, Wu YY, Hung CH, Lu SN, Lee CM, Chiu KW, Tsai MC, Tseng PL, Huang CM, Cho CL, Chen HH, Hu TH. Clinical-guide risk prediction of hepatocellular carcinoma development in chronic hepatitis C patients after interferon-based therapy. Br J Cancer 2013;109:2481-8. [PMID: 24084770 DOI: 10.1038/bjc.2013.564] [Cited by in Crossref: 49] [Cited by in F6Publishing: 42] [Article Influence: 6.1] [Reference Citation Analysis]
14 Kumada T, Toyoda H, Kiriyama S, Tanikawa M, Hisanaga Y, Kanamori A, Tada T, Tanaka J, Yoshizawa H. Predictive value of tumor markers for hepatocarcinogenesis in patients with hepatitis C virus. J Gastroenterol. 2011;46:536-544. [PMID: 21132575 DOI: 10.1007/s00535-010-0349-7] [Cited by in Crossref: 32] [Cited by in F6Publishing: 35] [Article Influence: 2.9] [Reference Citation Analysis]
15 Tejima K, Masuzaki R, Ikeda H, Yoshida H, Tateishi R, Sugioka Y, Kume Y, Okano T, Iwai T, Gotoh H. Thrombocytopenia is more severe in patients with advanced chronic hepatitis C than B with the same grade of liver stiffness and splenomegaly. J Gastroenterol. 2010;45:876-884. [PMID: 20339877 DOI: 10.1007/s00535-010-0233-5] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 1.5] [Reference Citation Analysis]
16 Surana P, Hercun J, Takyar V, Kleiner DE, Heller T, Koh C. Platelet count as a screening tool for compensated cirrhosis in chronic viral hepatitis. World J Gastrointest Pathophysiol 2021; 12(3): 40-50 [PMID: 34084591 DOI: 10.4291/wjgp.v12.i3.40] [Reference Citation Analysis]
17 Wong KM, Yeh ML, Chuang SC, Wang LY, Lin ZY, Chen SC, Tsai JF, Wang SN, Kuo KK, Dai CY, Yu ML, Lee KT, Chuang WL. Survival comparison between surgical resection and percutaneous radiofrequency ablation for patients in Barcelona Clinic Liver Cancer early stage hepatocellular carcinoma. Indian J Gastroenterol 2013;32:253-7. [PMID: 22932964 DOI: 10.1007/s12664-012-0225-x] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 2.1] [Reference Citation Analysis]
18 Mota A, Areias J, Cardoso MF. Chronic liver disease and cirrhosis among patients with hepatitis B virus infection in northern Portugal with reference to the viral genotypes. J Med Virol. 2011;83:71-77. [PMID: 21108341 DOI: 10.1002/jmv.21939] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 0.9] [Reference Citation Analysis]
19 Carr BI, Guerra V, Pancoska P. Thrombocytopenia in relation to tumor size in patients with hepatocellular carcinoma. Oncology. 2012;83:339-345. [PMID: 23006937 DOI: 10.1159/000342431] [Cited by in Crossref: 22] [Cited by in F6Publishing: 23] [Article Influence: 2.4] [Reference Citation Analysis]
20 Chang KC, Lu SN, Chen PF, Hung CH, Kee KM, Yen YH, Wang JH. Incidence and associated risk factors of hepatocellular carcinoma in a dural hepatitis B and C virus endemic area: a surveillance study. Kaohsiung J Med Sci 2011;27:85-90. [PMID: 21421195 DOI: 10.1016/j.kjms.2010.11.001] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
21 Kim HN, Newcomb CW, Carbonari DM, Roy JA, Torgersen J, Althoff KN, Kitahata MM, Reddy KR, Lim JK, Silverberg MJ, Mayor AM, Horberg MA, Cachay ER, Kirk GD, Sun J, Hull M, Gill MJ, Sterling TR, Kostman JR, Peters MG, Moore RD, Klein MB, Lo Re V 3rd; North American AIDS Cohort Collaboration on Research, Design of IeDEA. Risk of HCC With Hepatitis B Viremia Among HIV/HBV-Coinfected Persons in North America. Hepatology 2021. [PMID: 33780007 DOI: 10.1002/hep.31839] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
22 Tung HD, Wang JH, Tseng PL, Hung CH, Kee KM, Chen CH, Chang KC, Lee CM, Changchien CS, Chen YD, Lu SN. Neither diabetes mellitus nor overweight is a risk factor for hepatocellular carcinoma in a dual HBV and HCV endemic area: community cross-sectional and case-control studies. Am J Gastroenterol 2010;105:624-31. [PMID: 20051944 DOI: 10.1038/ajg.2009.711] [Cited by in Crossref: 36] [Cited by in F6Publishing: 39] [Article Influence: 3.3] [Reference Citation Analysis]
23 Mauss S, Hueppe D, John C, Goelz J, Heyne R, Moeller B, Link R, Teuber G, Herrmann A, Spelter M. Estimating the likelihood of sustained virological response in chronic hepatitis C therapy. J Viral Hepat. 2011;18:e81-e90. [PMID: 20849436 DOI: 10.1111/j.1365-2893.2010.01372.x] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 1.7] [Reference Citation Analysis]
24 Tung WC, Huang YJ, Leung SW, Kuo FY, Tung HD, Wang JH, Hung CH, Lee CM, Changchien CS, Yeh SA. Incidence of needle tract seeding and responses of soft tissue metastasis by hepatocellular carcinoma postradiotherapy. Liver Int. 2007;27:192-200. [PMID: 17311613 DOI: 10.1111/j.1478-3231.2006.01399.x] [Cited by in Crossref: 37] [Cited by in F6Publishing: 25] [Article Influence: 2.6] [Reference Citation Analysis]
25 Kaibori M, Kubo S, Nagano H, Hayashi M, Haji S, Nakai T, Ishizaki M, Matsui K, Uenishi T, Takemura S, Wada H, Marubashi S, Komeda K, Hirokawa F, Nakata Y, Uchiyama K, Kwon A. Clinicopathological Features of Recurrence in Patients After 10-year Disease-free Survival Following Curative Hepatic Resection of Hepatocellular Carcinoma. World J Surg 2013;37:820-8. [DOI: 10.1007/s00268-013-1902-3] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 1.8] [Reference Citation Analysis]
26 Kurosaki M, Hiramatsu N, Sakamoto M, Suzuki Y, Iwasaki M, Tamori A, Matsuura K, Kakinuma S, Sugauchi F, Sakamoto N, Nakagawa M, Izumi N. Data mining model using simple and readily available factors could identify patients at high risk for hepatocellular carcinoma in chronic hepatitis C. J Hepatol 2012;56:602-8. [PMID: 22027574 DOI: 10.1016/j.jhep.2011.09.011] [Cited by in Crossref: 21] [Cited by in F6Publishing: 17] [Article Influence: 2.1] [Reference Citation Analysis]
27 Chang KC, Hung CH, Lu SN, Wang JH, Lee CM, Chen CH, Yen MF, Lin SC, Yen YH, Tsai MC. A novel predictive score for hepatocellular carcinoma development in patients with chronic hepatitis C after sustained response to pegylated interferon and ribavirin combination therapy. J Antimicrob Chemother. 2012;67:2766-2772. [PMID: 22899800 DOI: 10.1093/jac/dks269] [Cited by in Crossref: 67] [Cited by in F6Publishing: 66] [Article Influence: 7.4] [Reference Citation Analysis]
28 Pavlovic N, Rani B, Gerwins P, Heindryckx F. Platelets as Key Factors in Hepatocellular Carcinoma. Cancers (Basel) 2019;11:E1022. [PMID: 31330817 DOI: 10.3390/cancers11071022] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 9.5] [Reference Citation Analysis]
29 Abdo AA, Hassanain M, AlJumah A, Al Olayan A, Sanai FM, Alsuhaibani HA, Abdulkareem H, Abdallah K, AlMuaikeel M, Al Saghier M, Babatin M, Kabbani M, Bazarbashi S, Metrakos P, Bruix J; Saudi Association for the Study of Liver Diseases and Transplantation., Saudi Oncology Society. Saudi guidelines for the diagnosis and management of hepatocellular carcinoma: technical review and practice guidelines. Ann Saudi Med 2012;32:174-99. [PMID: 22366832 DOI: 10.5144/0256-4947.2012.174] [Cited by in Crossref: 13] [Cited by in F6Publishing: 17] [Article Influence: 1.6] [Reference Citation Analysis]
30 Klammt S, Mitzner SR, Reisinger EC, Stange J. No sustained impact of intermittent extracorporeal liver support on thrombocyte time course in a randomized controlled albumin dialysis trial. Ther Apher Dial 2014;18:502-8. [PMID: 25195684 DOI: 10.1111/1744-9987.12124] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
31 Roshan B, Guzman G. Histological and clinical characteristics of patients with chronic hepatitis C and persistently normal alanine aminotransferase levels. Hepat Res Treat 2014;2014:760943. [PMID: 24891947 DOI: 10.1155/2014/760943] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
32 Tseng PL, Wang JH, Hung CH, Tung HD, Chen TM, Huang WS, Liu SL, Hu TH, Lee CM, Lu SN. Comparisons of noninvasive indices based on daily practice parameters for predicting liver cirrhosis in chronic hepatitis B and hepatitis C patients in hospital and community populations. Kaohsiung J Med Sci. 2013;29:385-395. [PMID: 23768703 DOI: 10.1016/j.kjms.2012.11.007] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 1.8] [Reference Citation Analysis]
33 Kumada T, Toyoda H, Tada T, Kiriyama S, Tanikawa M, Hisanaga Y, Kanamori A, Niinomi T, Yasuda S, Andou Y, Yamamoto K, Tanaka J. Effect of nucleos(t)ide analogue therapy on hepatocarcinogenesis in chronic hepatitis B patients: a propensity score analysis. J Hepatol. 2013;58:427-433. [PMID: 23123221 DOI: 10.1016/j.jhep.2012.10.025] [Cited by in Crossref: 95] [Cited by in F6Publishing: 90] [Article Influence: 10.6] [Reference Citation Analysis]
34 Huang CM, Hu TH, Chang KC, Tseng PL, Lu SN, Chen CH, Wang JH, Lee CM, Tsai MC, Lin MT, Yen YH, Hung CH, Cho CL, Wu CK. Dynamic noninvasive markers predict hepatocellular carcinoma in chronic hepatitis C patients without sustained virological response after interferon-based therapy: Prioritize who needs urgent direct-acting antiviral agents. Medicine (Baltimore) 2017;96:e8696. [PMID: 29145306 DOI: 10.1097/MD.0000000000008696] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
35 Li Q, Yu CH, Yu JH, Liu L, Xie SS, Li WW, Yang X, Fan WB, Gai ZT, Chen SJ. ABO blood group and the risk of hepatocellular carcinoma: a case-control study in patients with chronic hepatitis B. PLoS One. 2012;7:e29928. [PMID: 22235351 DOI: 10.1371/journal.pone.0029928] [Cited by in Crossref: 19] [Cited by in F6Publishing: 23] [Article Influence: 2.1] [Reference Citation Analysis]
36 Kumada T, Toyoda H, Kiriyama S, Sone Y, Tanikawa M, Hisanaga Y, Kanamori A, Atsumi H, Takagi M, Arakawa T, Fujimori M. Incidence of hepatocellular carcinoma in patients with chronic hepatitis B virus infection who have normal alanine aminotransferase values: HCC in HBV Carriers With Normal ALT. J Med Virol 2010;82:539-45. [DOI: 10.1002/jmv.21686] [Cited by in Crossref: 24] [Cited by in F6Publishing: 24] [Article Influence: 2.2] [Reference Citation Analysis]
37 Pancoska P, Lu SN, Carr BI. Phenotypic Categorization and Profiles of Small and Large Hepatocellular Carcinomas. J Gastrointest Dig Syst 2013;Suppl 12:001. [PMID: 23956952 DOI: 10.4172/2161-069X.S12-001] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
38 Kuo YH, Lu SN, Hung CH, Kee KM, Chen CH, Hu TH, Lee CM, Changchien CS, Wang JH. Liver stiffness measurement in the risk assessment of hepatocellular carcinoma for patients with chronic hepatitis. Hepatol Int 2010;4:700-6. [PMID: 21286340 DOI: 10.1007/s12072-010-9223-1] [Cited by in Crossref: 23] [Cited by in F6Publishing: 22] [Article Influence: 2.1] [Reference Citation Analysis]
39 Liu J, Chen J, Chen C, Wang J, Lin C, Chen P, Hung C, Kee K, Lee C, Tsai L, Chen S, Lin S, Lu S. Community-based cross-sectional study: The association of lipids with hepatitis C seropositivity and diabetes mellitus: Lipid relation HCV and diabetes mellitus. J Gastroenterol Hepatol 2012;27:1688-94. [DOI: 10.1111/j.1440-1746.2012.07212.x] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
40 Tsai M, Chen C, Hu T, Lu S, Lee C, Wang J, Hung C. Long-term outcomes of hepatitis B virus-related cirrhosis treated with nucleos(t)ide analogs. Journal of the Formosan Medical Association 2017;116:512-21. [DOI: 10.1016/j.jfma.2016.08.006] [Cited by in Crossref: 14] [Cited by in F6Publishing: 18] [Article Influence: 3.5] [Reference Citation Analysis]
41 Noritake H, Kobayashi Y, Ooba Y, Kitsugi K, Shimoyama S, Yamazaki S, Chida T, Watanabe S, Kawata K, Suda T. Improved Serum Alpha-Fetoprotein Levels after Iron Reduction Therapy in HCV Patients. ISRN Hepatol 2014;2014:875140. [PMID: 27335844 DOI: 10.1155/2014/875140] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
42 Hsieh YY, Tung SY, Lee K, Wu CS, Wei KL, Shen CH, Chang TS, Lin YH. Routine blood tests to predict liver fibrosis in chronic hepatitis C. World J Gastroenterol 2012; 18(8): 746-753 [PMID: 22371634 DOI: 10.3748/wjg.v18.i8.746] [Cited by in CrossRef: 21] [Cited by in F6Publishing: 21] [Article Influence: 2.3] [Reference Citation Analysis]
43 Carr BI, Guerra V. Validation of a Liver Index and Its Significance for HCC Aggressiveness. J Gastrointest Cancer 2017;48:262-6. [PMID: 28631027 DOI: 10.1007/s12029-017-9971-4] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
44 Shin HP, Lee JI, Jung JH, Yim SV, Kim HJ, Cha JM, Park JB, Joo KR, Hwang JS, Jang BK. Matrix metalloproteinase (MMP)-3 polymorphism in patients with HBV related chronic liver disease. Dig Dis Sci. 2008;53:823-829. [PMID: 17763953 DOI: 10.1007/s10620-007-9937-7] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
45 Kee KM, Wang JH, Hung CH, Chen CH, Lee CM, Chang KC, Tseng PL, Yen YH, Lin CY, Lu SN. Decreased anti-hepatitis C virus titer and associated factors in chronic hepatitis C patients after sustained virological response: a prospective study. J Gastroenterol Hepatol 2012;27:1106-11. [PMID: 22004331 DOI: 10.1111/j.1440-1746.2011.06946.x] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.1] [Reference Citation Analysis]
46 Jeng JE, Tsai JF, Chuang LY, Ho MS, Lin ZY, Hsieh MY, Chen SC, Chuang WL, Wang LY, Yu ML, Dai CY, Chang JG. Tumor necrosis factor-alpha 308.2 polymorphism is associated with advanced hepatic fibrosis and higher risk for hepatocellular carcinoma. Neoplasia 2007;9:987-92. [PMID: 18030367 DOI: 10.1593/neo.07781] [Cited by in Crossref: 68] [Cited by in F6Publishing: 61] [Article Influence: 4.9] [Reference Citation Analysis]
47 Berardi R, Santoni M, Rinaldi S, Bower M, Tiberi M, Morgese F, Caramanti M, Savini A, Ferrini C, Torniai M, Fiordoliva I, Newsom-Davis T. Pre-treatment systemic immune-inflammation represents a prognostic factor in patients with advanced non-small cell lung cancer. Ann Transl Med 2019;7:572. [PMID: 31807553 DOI: 10.21037/atm.2019.09.18] [Cited by in Crossref: 8] [Cited by in F6Publishing: 13] [Article Influence: 4.0] [Reference Citation Analysis]
48 Lu C, Qiu J, Huang P, Zou R, Hong J, Li B, Chen G, Yuan Y. NADPH oxidase DUOX1 and DUOX2 but not NOX4 are independent predictors in hepatocellular carcinoma after hepatectomy. Tumor Biol 2011;32:1173-82. [DOI: 10.1007/s13277-011-0220-3] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 2.0] [Reference Citation Analysis]
49 Li C, Li X, Huang F, Yang J, Wu A, Wang L, Qin D, Zou W, Wu J. Efficacy and Safety of Avatrombopag in Patients With Thrombocytopenia: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Front Pharmacol 2019;10:829. [PMID: 31402863 DOI: 10.3389/fphar.2019.00829] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
50 Kobeisy MA, Morsy KH, Galal M, Sayed SK, Ashmawy MM, Mohammad FM. Clinical significance of elevated alpha-foetoprotein (AFP) in patients with chronic hepatitis C without hepatocellular carcinoma in upper EGYPT. Arab J Gastroenterol. 2012;13:49-53. [PMID: 22980591 DOI: 10.1016/j.ajg.2012.06.004] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 1.4] [Reference Citation Analysis]
51 Shan R, Yin H, Yang W, Li J, Zhang M, Zhao M, Shao J, Wang A. Influencing factors of transient elastography in detecting liver stiffness. Exp Ther Med 2016;12:2302-6. [PMID: 27698728 DOI: 10.3892/etm.2016.3617] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
52 Carr BI, Guerra V, Giannini EG, Farinati F, Ciccarese F, Rapaccini GL, Di Marco M, Benvegnù L, Zoli M, Borzio F, Caturelli E, Masotto A, Trevisani F. A Liver Index and its Relationship to Indices of HCC Aggressiveness. J Integr Oncol 2016;5:178. [PMID: 28580457 DOI: 10.4172/2329-6771.1000178] [Cited by in Crossref: 10] [Cited by in F6Publishing: 16] [Article Influence: 2.0] [Reference Citation Analysis]
53 Hung IF, Poon RT, Lai CL, Fung J, Fan ST, Yuen MF. Recurrence of hepatitis B-related hepatocellular carcinoma is associated with high viral load at the time of resection. Am J Gastroenterol. 2008;103:1663-1673. [PMID: 18616655 DOI: 10.1111/j.1572-0241.2008.01872.x] [Cited by in Crossref: 122] [Cited by in F6Publishing: 124] [Article Influence: 9.4] [Reference Citation Analysis]
54 Qureshi K, Patel S, Meillier A. The Use of Thrombopoietin Receptor Agonists for Correction of Thrombocytopenia prior to Elective Procedures in Chronic Liver Diseases: Review of Current Evidence. Int J Hepatol 2016;2016:1802932. [PMID: 27800187 DOI: 10.1155/2016/1802932] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 3.4] [Reference Citation Analysis]
55 Wang JH, Chang KC, Kee KM, Chen PF, Yen YH, Tseng PL, Kuo YH, Tsai MC, Hung CH, Chen CH. Hepatocellular carcinoma surveillance at 4- vs. 12-month intervals for patients with chronic viral hepatitis: a randomized study in community. Am J Gastroenterol. 2013;108:416-424. [PMID: 23318478 DOI: 10.1038/ajg.2012.445] [Cited by in Crossref: 42] [Cited by in F6Publishing: 37] [Article Influence: 5.3] [Reference Citation Analysis]
56 Carr BI, Lin CY, Lu SN. Platelet-related phenotypic patterns in hepatocellular carcinoma patients. Semin Oncol 2014;41:415-21. [PMID: 25023358 DOI: 10.1053/j.seminoncol.2014.04.001] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 2.6] [Reference Citation Analysis]
57 Kawaguchi T, Komori A, Seike M, Fujiyama S, Watanabe H, Tanaka M, Sakisaka S, Nakamuta M, Sasaki Y, Oketani M, Hattori T, Katsura K, Sata M. Efficacy and safety of eltrombopag in Japanese patients with chronic liver disease and thrombocytopenia: a randomized, open-label, phase II study. J Gastroenterol 2012;47:1342-51. [PMID: 22674141 DOI: 10.1007/s00535-012-0600-5] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 2.2] [Reference Citation Analysis]
58 Tseng PL, Wang JH, Tung HD, Hung CH, Kee KM, Chen CH, Chang KC, Lee CM, Changchien CS, Chen PF. Optimal treatment increased survival of hepatocellular carcinoma patients detected with community-based screening. J Gastroenterol Hepatol. 2010;25:1426-1434. [PMID: 20659234 DOI: 10.1111/j.1440-1746.2010.06285.x] [Cited by in Crossref: 25] [Cited by in F6Publishing: 27] [Article Influence: 2.3] [Reference Citation Analysis]
59 Lin CL, Kao JH. Optimal management of hepatocellular carcinoma: challenges and opportunities. J Gastroenterol Hepatol 2010;25:1336-8. [PMID: 20659219 DOI: 10.1111/j.1440-1746.2010.06373.x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
60 Lai Q, Vitale A, Manzia TM, Foschi FG, Levi Sandri GB, Gambato M, Melandro F, Russo FP, Miele L, Viganò L, Burra P, Giannini EG; Associazione Italiana per lo Studio del Fegato (AISF) HCC Special Interest Group. Platelets and Hepatocellular Cancer: Bridging the Bench to the Clinics. Cancers (Basel) 2019;11:E1568. [PMID: 31618961 DOI: 10.3390/cancers11101568] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
61 Minami T, Tateishi R, Kondo M, Nakagomi R, Fujiwara N, Sato M, Uchino K, Enooku K, Nakagawa H, Asaoka Y, Kondo Y, Moriya K, Shiina S, Koike K. Serum Alpha-Fetoprotein Has High Specificity for the Early Detection of Hepatocellular Carcinoma After Hepatitis C Virus Eradication in Patients. Medicine (Baltimore) 2015;94:e901. [PMID: 26061310 DOI: 10.1097/MD.0000000000000901] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
62 Zanetto A, Senzolo M, Ferrarese A, Simioni P, Burra P, Rodríguez-castro KI. Assessment of Bleeding Risk in Patients with Cirrhosis. Curr Hepatology Rep 2015;14:9-18. [DOI: 10.1007/s11901-015-0250-1] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
63 Tsai JF, Chen SC, Lin ZY, Dai CY, Huang JF, Yu ML, Chuang WL. Independent and additive interaction between polymorphisms of tumor necrosis factor α-308 and lymphotoxin α+252 on risk of hepatocellular carcinoma related to hepatitis B. Kaohsiung J Med Sci 2017;33:453-7. [PMID: 28865603 DOI: 10.1016/j.kjms.2017.04.009] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
64 El-Zefzafy W, Eltokhy H, Mohamed NA, Abu-Zahab Z. Significance of Serum Cytokeratin-18 in Prediction of Hepatocellular Carcinoma in Chronic Hepatitis C Infected Egyptian Patients. Open Access Maced J Med Sci 2015;3:117-23. [PMID: 27275207 DOI: 10.3889/oamjms.2015.021] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
65 Kee KM, Wang JH, Hung CH, Chen CH, Lee CM, Lu SN. Improvement of thrombocytopenia in hepatitis C-related advanced fibrosis patients after sustained virological response. Dig Dis Sci 2013;58:556-61. [PMID: 23001404 DOI: 10.1007/s10620-012-2380-4] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
66 Carr BI, Guerra V, De Giorgio M, Fagiuoli S, Pancoska P. Small hepatocellular carcinomas and thrombocytopenia. Oncology 2012;83:331-8. [PMID: 23006906 DOI: 10.1159/000341533] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 1.8] [Reference Citation Analysis]
67 Da BL, Surana P, Kleiner DE, Heller T, Koh C. The Delta-4 fibrosis score (D4FS): A novel fibrosis score in chronic hepatitis D. Antiviral Res 2020;174:104691. [PMID: 31837393 DOI: 10.1016/j.antiviral.2019.104691] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
68 Amano H, Tashiro H, Oshita A, Kobayashi T, Tanimoto Y, Kuroda S, Tazawa H, Itamoto T, Asahara T, Ohdan H. Significance of Platelet Count in the Outcomes of Hepatectomized Patients with Hepatocellular Carcinoma Exceeding the Milan Criteria. J Gastrointest Surg 2011;15:1173-81. [DOI: 10.1007/s11605-011-1538-2] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 2.0] [Reference Citation Analysis]
69 Selph SS, Ginsburg AD, Chou R. Impact of contacting study authors to obtain additional data for systematic reviews: diagnostic accuracy studies for hepatic fibrosis. Syst Rev 2014;3:107. [PMID: 25239493 DOI: 10.1186/2046-4053-3-107] [Cited by in Crossref: 31] [Cited by in F6Publishing: 32] [Article Influence: 4.4] [Reference Citation Analysis]
70 Zhong LK, Zhang G, Luo SY, Yin W, Song HY. The value of platelet count in evaluating the degree of liver fibrosis in patients with chronic hepatitis B. J Clin Lab Anal 2020;34:e23270. [PMID: 32363594 DOI: 10.1002/jcla.23270] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
71 Kawaratani H, Tsuji Y, Ishida K, Kaya D, Kubo T, Fujinaga Y, Sawada Y, Sato S, Takaya H, Kaji K, Namisaki T, Moriya K, Akahane T, Yoshiji H. Effect of three or more treatments with lusutrombopag in patients with cirrhotic thrombocytopenia: A retrospective single-center study. Hepatol Res 2020;50:1101-5. [PMID: 32558192 DOI: 10.1111/hepr.13536] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
72 Carr BI, Guerra V. Thrombocytosis and hepatocellular carcinoma. Dig Dis Sci. 2013;58:1790-1796. [PMID: 23314854 DOI: 10.1007/s10620-012-2527-3] [Cited by in Crossref: 42] [Cited by in F6Publishing: 40] [Article Influence: 5.3] [Reference Citation Analysis]
73 Carr BI, Guerra V. Hepatocellular carcinoma size: platelets, γ-glutamyl transpeptidase, and alkaline phosphatase. Oncology. 2013;85:153-159. [PMID: 23988857 DOI: 10.1159/000354416] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 2.6] [Reference Citation Analysis]
74 Lok AS, Seeff LB, Morgan TR, di Bisceglie AM, Sterling RK, Curto TM, Everson GT, Lindsay KL, Lee WM, Bonkovsky HL, Dienstag JL, Ghany MG, Morishima C, Goodman ZD;  HALT-C Trial Group. Incidence of hepatocellular carcinoma and associated risk factors in hepatitis C-related advanced liver disease. Gastroenterology. 2009;136:138-148. [PMID: 18848939 DOI: 10.1053/j.gastro.2008.09.014] [Cited by in Crossref: 401] [Cited by in F6Publishing: 368] [Article Influence: 30.8] [Reference Citation Analysis]
75 Burak KW, Coffin CS, Myers RP. Hepatitis B awareness and education: a failing grade. Can J Gastroenterol 2011;25:125-6. [PMID: 21499575 DOI: 10.1155/2011/956763] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
76 Teriaky A, Reau N. Evaluation of Hepatitis C Patients in the Direct-Acting Antiviral Era. Clin Liver Dis 2015;19:591-604, v. [PMID: 26466649 DOI: 10.1016/j.cld.2015.06.001] [Reference Citation Analysis]
77 Yeh YP, Hu TH, Cho PY, Chen HH, Yen AM, Chen SL, Chiu SY, Fann JC, Su WW, Fang YJ. Evaluation of abdominal ultrasonography mass screening for hepatocellular carcinoma in Taiwan. Hepatology. 2014;59:1840-1849. [PMID: 24002724 DOI: 10.1002/hep.26703] [Cited by in Crossref: 45] [Cited by in F6Publishing: 46] [Article Influence: 6.4] [Reference Citation Analysis]
78 Chen JY, Wang JH, Lin CY, Chen PF, Tseng PL, Chen CH, Chang KC, Tsai LS, Chen SC, Lu SN. Lower prevalence of hypercholesterolemia and hyperglyceridemia found in subjects with seropositivity for both hepatitis B and C strains independently. J Gastroenterol Hepatol. 2010;25:1763-1768. [PMID: 21039839 DOI: 10.1111/j.1440-1746.2010.06300.x] [Cited by in Crossref: 29] [Cited by in F6Publishing: 29] [Article Influence: 2.9] [Reference Citation Analysis]
79 Huang Y, Huang C, Chang K, Hung S, Wang J, Hung C, Chen C, Tseng P, Kee K, Yen Y, Tsai P, Tsai C, Lu S. Community-based screening for hepatocellular carcinoma in elderly residents in a hepatitis B- and C-endemic area: Hepatoma screening in an aged population. Journal of Gastroenterology and Hepatology 2011;26:129-34. [DOI: 10.1111/j.1440-1746.2010.06476.x] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 1.5] [Reference Citation Analysis]
80 Maan R, van der Meer AJ, Hansen BE, Feld JJ, Wedemeyer H, Dufour JF, Zangneh HF, Lammert F, Manns MP, Zeuzem S, Janssen HL, de Knegt RJ, Veldt BJ. Effect of thrombocytopenia on treatment tolerability and outcome in patients with chronic HCV infection and advanced hepatic fibrosis. J Hepatol 2014;61:482-91. [PMID: 24780302 DOI: 10.1016/j.jhep.2014.04.021] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 2.1] [Reference Citation Analysis]
81 Lv X, Yang F, Guo X, Yang T, Zhou T, Dong X, Long Y, Xiao D, Chen Y. Hypersplenism is correlated with increased risk of hepatocellular carcinoma in patients with post-hepatitis cirrhosis. Tumour Biol. 2016;37:8889-8900. [PMID: 26753954 DOI: 10.1007/s13277-015-4764-5] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 2.2] [Reference Citation Analysis]
82 Li J, Li J, Bao Y, Pan K, Lin X, Liu X, Wang H, Xu Y, Luo X, Li H, Duan C. Low Frequency of Peripheral Lymphocyte in Chronic Hepatitis B Patients Predicts Poor Progression to Hepatocellular Carcinoma. J Clin Lab Anal 2016;30:208-15. [PMID: 25600684 DOI: 10.1002/jcla.21838] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
83 Abdelmoneim SS, Talwalkar J, Sethi S, Kamath P, Fathalla MM, Kipp BR, Campion MB, Clayton AC, Halling KC, Shah VH. A prospective pilot study of circulating endothelial cells as a potential new biomarker in portal hypertension. Liver Int 2010;30:191-7. [PMID: 19840257 DOI: 10.1111/j.1478-3231.2009.02132.x] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 1.3] [Reference Citation Analysis]
84 Lambert MP. Platelets in liver and renal disease. Hematology Am Soc Hematol Educ Program. 2016;2016:251-255. [PMID: 27913488 DOI: 10.1182/asheducation-2016.1.251] [Cited by in Crossref: 21] [Cited by in F6Publishing: 17] [Article Influence: 5.3] [Reference Citation Analysis]
85 Carr BI, Guerra V, Giannini EG, Farinati F, Ciccarese F, Rapaccini GL, Di Marco M, Benvegnù L, Zoli M, Borzio F, Caturelli E, Chiaramonte M, Trevisani F; Italian Liver Cancer Group. Significance of platelet and AFP levels and liver function parameters for HCC size and survival. Int J Biol Markers 2014;29:e215-23. [PMID: 24526315 DOI: 10.5301/jbm.5000064] [Cited by in Crossref: 19] [Cited by in F6Publishing: 22] [Article Influence: 2.7] [Reference Citation Analysis]
86 Kuo YH, Lu SN, Chen CL, Cheng YF, Lin CY, Hung CH, Chen CH, Changchien CS, Hsu HC, Hu TH. Hepatocellular carcinoma surveillance and appropriate treatment options improve survival for patients with liver cirrhosis. Eur J Cancer. 2010;46:744-751. [PMID: 20060710 DOI: 10.1016/j.ejca.2009.12.018] [Cited by in Crossref: 67] [Cited by in F6Publishing: 66] [Article Influence: 6.1] [Reference Citation Analysis]
87 Ioannou GN, Green P, Lowy E, Mun EJ, Berry K. Differences in hepatocellular carcinoma risk, predictors and trends over time according to etiology of cirrhosis. PLoS One 2018;13:e0204412. [PMID: 30260995 DOI: 10.1371/journal.pone.0204412] [Cited by in Crossref: 29] [Cited by in F6Publishing: 31] [Article Influence: 9.7] [Reference Citation Analysis]
88 Farrell C, Hayes SC, Wire M, Zhang J. Population pharmacokinetic/pharmacodynamic modelling of eltrombopag in healthy volunteers and subjects with chronic liver disease. Br J Clin Pharmacol 2014;77:532-44. [PMID: 24117976 DOI: 10.1111/bcp.12244] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.1] [Reference Citation Analysis]
89 Aravalli RN, Steer CJ. Immune-Mediated Therapies for Liver Cancer. Genes (Basel) 2017;8:E76. [PMID: 28218682 DOI: 10.3390/genes8020076] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 2.5] [Reference Citation Analysis]
90 Kuo MJ, Chen HH, Chen CL, Fann JCY, Chen SLS, Chiu SYH, Lin YM, Liao CS, Chang HC, Lin YS, Yen AMF. Cost-effectiveness analysis of population-based screening of hepatocellular carcinoma: Comparing ultrasonography with two-stage screening. World J Gastroenterol 2016; 22(12): 3460-3470 [PMID: 27022228 DOI: 10.3748/wjg.v22.i12.3460] [Cited by in CrossRef: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.6] [Reference Citation Analysis]
91 Lippolis C, Refolo MG, D'Alessandro R, Carella N, Messa C, Cavallini A, Carr BI. Resistance to multikinase inhibitor actions mediated by insulin like growth factor-1. J Exp Clin Cancer Res 2015;34:90. [PMID: 26329608 DOI: 10.1186/s13046-015-0210-1] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 2.5] [Reference Citation Analysis]
92 Kobayashi M, Akuta N, Suzuki F, Hosaka T, Sezaki H, Kobayashi M, Suzuki Y, Arase Y, Ikeda K, Watahiki S, Mineta R, Iwasaki S, Miyakawa Y, Kumada H. Influence of amino-acid polymorphism in the core protein on progression of liver disease in patients infected with hepatitis C virus genotype 1b. J Med Virol 2010;82:41-8. [DOI: 10.1002/jmv.21629] [Cited by in Crossref: 22] [Cited by in F6Publishing: 23] [Article Influence: 2.0] [Reference Citation Analysis]
93 Kee K, Lu S. Hospital- and Community-Based Screenings for Hepatocellular Carcinoma in Taiwan. Oncology 2011;81:36-40. [DOI: 10.1159/000333257] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 1.2] [Reference Citation Analysis]
94 Bräu N. Evaluation of the hepatitis C virus-infected patient: the initial encounter. Clin Infect Dis. 2013;56:853-860. [PMID: 23243172 DOI: 10.1093/cid/cis957] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
95 Maan R, Zaim R, van der Meer AJ, Feld JJ, Wedemeyer H, Dufour JF, Lammert F, Manns MP, Zeuzem S, Hansen BE, Janssen H, Veldt BJ, de Knegt RJ, Uyl-de Groot CA. Real-world medical costs of antiviral therapy among patients with chronic HCV infection and advanced hepatic fibrosis. J Gastroenterol Hepatol 2016;31:1851-9. [PMID: 26990109 DOI: 10.1111/jgh.13373] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
96 Tai WC, Hu TH, Wang JH, Hung CH, Lu SN, Changchien CS, Lee CM. Clinical implications of alpha-fetoprotein in chronic hepatitis C. J Formos Med Assoc 2009;108:210-8. [PMID: 19293036 DOI: 10.1016/S0929-6646(09)60054-1] [Cited by in Crossref: 23] [Cited by in F6Publishing: 10] [Article Influence: 1.9] [Reference Citation Analysis]
97 Ikarashi Y, Kodama K, Taniai M, Hashimoto E, Tokushige K. The Clinical Difference in the Platelet Counts between Liver Cirrhosis with Nonalcoholic Fatty Liver Disease and Hepatitis C Virus. Intern Med 2018;57:1065-70. [PMID: 29269684 DOI: 10.2169/internalmedicine.9853-17] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
98 Da BL, Surana P, Takyar V, Kleiner DE, Heller T, Koh C. Vibration-controlled transient elastography for the detection of cirrhosis in chronic hepatitis D infection. J Viral Hepat 2020;27:428-36. [PMID: 31742822 DOI: 10.1111/jvh.13235] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
99 Giuliante F, De Rose AM, Guerra V, Ardito F, Nuzzo G, Carr BI. Clinical characteristics and survival of European patients with resectable large hepatocellular carcinomas. J Gastrointest Cancer 2013;44:329-35. [PMID: 23912605 DOI: 10.1007/s12029-013-9523-5] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
100 Chen TM, Huang PT, Tsai MH, Lin LF, Liu CC, Ho KS, Siauw CP, Chao PL, Tung JN. Predictors of alpha-fetoprotein elevation in patients with chronic hepatitis C, but not hepatocellular carcinoma, and its normalization after pegylated interferon alfa 2a-ribavirin combination therapy. J Gastroenterol Hepatol. 2007;22:669-675. [PMID: 17444854 DOI: 10.1111/j.1440-1746.2007.04898.x] [Cited by in Crossref: 61] [Cited by in F6Publishing: 62] [Article Influence: 4.4] [Reference Citation Analysis]
101 Kumada T, Toyoda H, Kiriyama S, Sone Y, Tanikawa M, Hisanaga Y, Kanamori A, Atsumi H, Takagi M, Nakano S, Arakawa T, Fujimori M. Incidence of hepatocellular carcinoma in hepatitis C carriers with normal alanine aminotransferase levels. Journal of Hepatology 2009;50:729-35. [DOI: 10.1016/j.jhep.2008.11.019] [Cited by in Crossref: 36] [Cited by in F6Publishing: 37] [Article Influence: 3.0] [Reference Citation Analysis]
102 Terrault N, Chen YC, Izumi N, Kayali Z, Mitrut P, Tak WY, Allen LF, Hassanein T. Avatrombopag Before Procedures Reduces Need for Platelet Transfusion in Patients With Chronic Liver Disease and Thrombocytopenia. Gastroenterology. 2018;155:705-718. [PMID: 29778606 DOI: 10.1053/j.gastro.2018.05.025] [Cited by in Crossref: 79] [Cited by in F6Publishing: 64] [Article Influence: 26.3] [Reference Citation Analysis]